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Scientific comment
Comments on the clinical and laboratory characteristics of 
patients with dengue hemorrhagic fever manifestations and 
their transfusion profile
Romélia Pinheiro Gonçalves Lemes*
Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil
Transmitted by mosquitoes of the genus Aedes, dengue fever is 
a viral disease caused by one of four serotypes: DENV1, DENV2, 
DENV3 and DENV4.1 It is considered a public health problem 
worldwide. It is estimated that about 40 million symptomatic 
infections occur annually, of which about 2 million require 
hospitalization,2 resulting in about 20,000 deaths.3
The infection is characterized by a broad spectrum of 
clinical presentations, ranging from mild foot swelling 
to death.4 Thrombocytopenia is a prominent feature 
of infection.5 A platelet count less than 100 × 109/L is a 
diagnostic criterion for dengue hemorrhagic fever (DHF).6 
However, severe thrombocytopenia may be observed both 
in dengue fever (DF) and DHF. There is a significant negative 
correlation between disease severity and platelet count.7 
Thrombocytopenia and hypofibrinogenemia are responsible 
for changes in hemostasis but are not considered predictive 
markers of hemorrhage.8 The cause of thrombocytopenia 
in dengue is multifactorial and not fully understood; the 
mechanisms involved are bone marrow suppression and 
peripheral platelet destruction. Peripheral immune complex 
mediated destruction is probably the main contributor to 
thrombocytopenia in dengue infection.8
The characteristic clinical manifestations of dengue are 
fever, headache, retro-orbital pain, general malaise, arthralgia, 
rash, pruritus, diarrhea, nausea, respiratory distress, dry cough, 
painful hepatomegaly, continuous abdominal pain, vomiting, 
postural dizziness, sweating, hypothermia and bleeding.9 
Hemorrhagic manifestations, such as epistaxis, gingival 
bleeding, menorrhagia, gastrointestinal bleeding, intracranial 
bleeding, hematuria, effusions and spontaneous bleeding in 
places of venipuncture10 can be used as warning signs in the 
evolution of dengue.11 Among laboratory findings, an increase 
in hematocrit, leukopenia, relative lymphocytosis, atypical 
lymphocytes, low platelet count, prolonged prothrombin time 
(PT) and activated partial thromboplastin time (aPTT) and 
increased serum aspartate aminotransferase (AST), serum 
alanine aminotransferase (ALT), alkaline phosphatase and 
serum gamma-glutamyl transferase (GT) range and decreased 
serum albumin may occur.9-11
Prophylactic transfusion of platelet concentrate (PC) is 
indicated in patients without any history of bleeding but 
with a platelet count lower than 20 × 109/L, and transfusion 
therapy in patients with chronic active bleeding and platelet 
count lower than 50 × 109/L.12 Several studies have shown 
that there is a correlation between the bleeding degree and 
the platelet count.13-15 The prevention of bleeding in DHF 
should be directed to the early recognition of shock and 
immediate correction with PC of and/or fresh frozen plasma 
(FFP) transfusions.13,16,17 The monitoring of hematocrit in 
series, which reflects the degree of plasma leakage, at the 
expense of monitoring thrombocytopenia and coagulopathies 
results in a reduction in the use of blood products.17 Fugimoto 
& Koifman, based on secondary data from patients with DHF 
admitted to hospitals in Rio Branco, Acre, reported that the 
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clinical and laboratory profile of patients is similar to those 
described in the literature.18 As the transfusion of FFP and 
PC proved ineffective, there is currently limited support for 
the use of prophylactic PC transfusions in cases of dengue, 
despite its inclusion in some national guidelines. Therefore, 
it is necessary to conduct clinical trials to build an evidence 
base to guide the appropriate use of platelets in dengue. In 
summary, in the opinion of many authors prophylactic platelet 
transfusions in patients with stable dengue and without risk 
of bleeding can be avoided without affecting patient safety 
factors.
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